» Articles » PMID: 29492767

Surgical Treatment of Large Vestibular Schwannomas in Patients with Neurofibromatosis Type 2: Outcomes on Facial Nerve Function and Hearing Preservation

Overview
Journal J Neurooncol
Publisher Springer
Date 2018 Mar 2
PMID 29492767
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Surgical treatment of vestibular schwannoma (VS) in patients with neurofibromatosis type 2 (NF2) along with functional preservation of cranial nerves is challenging. The aim of this study was to analyze the outcomes of hearing and facial nerve function in patients with NF2 who underwent large-size VS (> 2 cm) surgery. From 2006 to 2016, one hundred and forty NF2 patients were included with 149 large-size VS resections using retrosigmoid approach. Hearing function was classified according to the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) criteria. Preoperative and one-year postoperative facial nerve function were both assessed using the House-Brackmann (H-B) grading scale. A multivariate logistic regression was performed to identify preoperative predictors for facial function outcomes. No operative death we noted. Total tumor removal was achieved in 82.6% of the operated VSs. The anatomical integrity of the facial nerve was preserved in 67.8% of surgeries. Good facial nerve function (H-B Grades I-III) was maintained in 49.6% of patients at 12 months after surgery. Tumor size larger than 3 cm and preoperative facial weakness related with worse outcome of facial nerve function (P < 0.001; for both). Hearing preservation surgeries were attempted in 31 ears. Class B or C hearing according to the AAO-HNS criteria was maintained in 7 ears (22.5%), and measurable hearing was maintained 11 ears (35.5%). It is challenging to maintain hearing and facial nerve function in NF2 patients with large VSs. Early surgical intervention is an appropriate choice to decrease the risk of neurological functions deficit.

Citing Articles

Analysis of the effect of neuroendoscopy-assisted microscopy in the treatment of Large (Koos grade IV) vestibular schwannoma.

Yang Z, Xiong X, Jian Z, Du L Front Oncol. 2023; 13:1033954.

PMID: 36733306 PMC: 9887138. DOI: 10.3389/fonc.2023.1033954.


Qu-Du-San-Jie decoction induces growth inhibition and vascular normalization in NF2-associated vestibular schwannoma.

Lin J, Li S, Zhang J, Chu F, Li C, Bie Z Front Pharmacol. 2022; 13:941854.

PMID: 36059985 PMC: 9437245. DOI: 10.3389/fphar.2022.941854.


Establishment of nomograms for the prediction of useful hearing loss in patients with neurofibromatosis type 2.

Li S, Zhang J, Tang H, Li P, Wang B, Zhao F J Neurooncol. 2021; 155(3):373-381.

PMID: 34751884 DOI: 10.1007/s11060-021-03889-2.


Gene Expression, Network Analysis, and Drug Discovery of Neurofibromatosis Type 2-Associated Vestibular Schwannomas Based on Bioinformatics Analysis.

Huang Q, Zhai S, Liao X, Liu Y, Yin S J Oncol. 2020; 2020:5976465.

PMID: 32733557 PMC: 7378604. DOI: 10.1155/2020/5976465.


Therapy of Sporadic and NF2-Related Vestibular Schwannoma.

Yao L, Alahmari M, Temel Y, Hovinga K Cancers (Basel). 2020; 12(4).

PMID: 32244314 PMC: 7226024. DOI: 10.3390/cancers12040835.


References
1.
Slattery 3rd W, Fisher L, Hitselberger W, Friedman R, Brackmann D . Hearing preservation surgery for neurofibromatosis Type 2-related vestibular schwannoma in pediatric patients. J Neurosurg. 2007; 106(4 Suppl):255-60. DOI: 10.3171/ped.2007.106.4.255. View

2.
Jaaskelainen J, Paetau A, Pyykko I, Blomstedt G, Palva T, Troupp H . Interface between the facial nerve and large acoustic neurinomas. Immunohistochemical study of the cleavage plane in NF2 and non-NF2 cases. J Neurosurg. 1994; 80(3):541-7. DOI: 10.3171/jns.1994.80.3.0541. View

3.
Mautner V, Lindenau M, Baser M, Hazim W, Tatagiba M, Haase W . The neuroimaging and clinical spectrum of neurofibromatosis 2. Neurosurgery. 1996; 38(5):880-5; discussion 885-6. DOI: 10.1097/00006123-199605000-00004. View

4.
Odat H, Piccirillo E, Sequino G, Taibah A, Sanna M . Management strategy of vestibular schwannoma in neurofibromatosis type 2. Otol Neurotol. 2011; 32(7):1163-70. DOI: 10.1097/MAO.0b013e3182267f17. View

5.
Kanzaki J, Tos M, Sanna M, Moffat D, Monsell E, Berliner K . New and modified reporting systems from the consensus meeting on systems for reporting results in vestibular schwannoma. Otol Neurotol. 2003; 24(4):642-8; discussion 648-9. DOI: 10.1097/00129492-200307000-00019. View